Transcription Factor Expression in Cell Lines Derived from Natural Killer-Cell and Natural Killer-Like T-Cell Leukemia-Lymphoma

Human Cell ◽  
2008 ◽  
Vol 17 (2) ◽  
pp. 85-92 ◽  
Author(s):  
Yoshinobu MATSUO ◽  
Hans G. DREXLER ◽  
Akira HARASHIMA ◽  
Ayumi OKOCHI ◽  
Norio SHIMIZU ◽  
...  
2008 ◽  
Vol 79 (3) ◽  
pp. 430-435 ◽  
Author(s):  
S. BANDYOPADHYAY ◽  
U. ZIEGNER ◽  
D.E. CAMPBELL ◽  
D.S. MILLER ◽  
J.A. HOXIE ◽  
...  

Reports ◽  
2018 ◽  
Vol 1 (2) ◽  
pp. 13
Author(s):  
Keisuke Teshigawara ◽  
Sho Nagai ◽  
Gaowa Bai ◽  
Yuji Okubo ◽  
Haorile Chagan-Yasutan ◽  
...  

Adult T-cell leukemia (ATL) is an indolent leukemia caused by type 1 human T-cell leukemia virus (HTLV-1). A variety of therapeutic interventions via immunological approaches have been attempted. ATL cells express costimulatory molecules of natural killer (NK) cells, and a new modality—amplified NK (ANK) cell treatment—was administered here to a patient with ATL. A 70-year-old female presenting with ringworm infection received a diagnosis of smoldering ATL in 2004. Monitoring of soluble IL-2 receptors (sIL-2Rs) in the serum showed disease exacerbation in 2007, associated with the enlargement of lymph nodes and formation of a skin tumor. NK cells were amplified by in vitro cell culture methods. To avoid cytokine release syndrome, 2–5 × 108 cells were administered with each injection. A total of 15 injections from 12 November 2007 to 15 February 2008 were administered to this patient. This case showed drastic downregulation of sIL-2R, resulting in the induction of complete remission, which lasted for >5 years. This is the first report of treatment of a patient with ATL using ANK cell therapy. More attempts of this therapy will enhance our insight into the appropriate application of this new therapy to clinically diverse patients.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1242-1242
Author(s):  
Meghana Kamath ◽  
Isaac Houston ◽  
Alexander Janovski ◽  
Xiang Zhu ◽  
Sivakumar Gowrisankar ◽  
...  

Abstract The Ets transcription factor PU.1 (encoded by the gene Sfpi1) functions in a concentration-dependent manner as a hematopoietic cell fate determinant. PU.1 levels are uniform in early hematopoiesis, increase during myeloid differentiation, and decrease after erythrocyte and T cell/natural killer cell commitment. It is unknown how downstream target genes respond to changes in PU.1 concentration. To address this, we generated mice with two distinct hypomorphic alleles of Sfpi1 and analyzed interleukin-3 dependent cell lines from fetal liver cells homozygous for either allele. PU.1 was produced in these cells at ∼20% (Sfpi1BN/BN) or ∼2% (Sfpi1Blac/Blac) of wild type. These cells fail to terminally differentiate as a consequence of low PU.1 expression and can be maintained as cell lines. To determine what groups of genes are expressed in response to two distinct PU.1 concentrations, we performed whole-genome microarray analysis and compared gene expression in Sfpi1BN/BN and Sfpi1Blac/Blac cell lines to Sfpi1−/− cell lines. Groups of downstream target genes were activated or repressed in four modes in response to the two discrete concentrations of PU.1: at higher but not lower PU.1 concentration, at lower but not higher PU.1 concentration, at both lower and higher concentration, and in a gradient fashion. We decided to focus on genes regulated in a gradient manner, because dose-dependency suggests that these may be direct targets of PU.1. Genes activated in a gradient manner were mostly myeloid-specific and enriched for target genes of PU.1. Genes repressed in a gradient manner included erythroid-specific genes and, unexpectedly, T cell and natural killer cell-specific genes. T cell genes were also repressed by PU.1 in cultured progenitor-B cells. With this unique allelic system, we can study three discrete concentrations of PU.1 at 20%, 2%, and 0% to examine concentration-dependent effects of PU.1 on target genes and lineage decisions. Overall, our results suggest that PU.1 functions in a concentration-dependent manner to promote myeloid differentiation and repress T cell or natural killer cell development.


2017 ◽  
Vol 12 (1) ◽  
Author(s):  
Xiaoke Jin ◽  
Youhai Xu ◽  
Jun Zhang ◽  
Guangxi Li ◽  
Dongping Huang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document